Recommended Conferences

Clinical Pharmacy and Pharmacology

Paris, France
 

Quantitative effects on cardiovascular risk factors and coronary heart disease risk of replacing partially hydrogenated vegetable oils with other fats and oils

Author(s): Mozaffarian D, Clarke R

Abstract

Background/objectives: Reduced consumption of trans-fatty acids (TFA) is desirable to lower coronary heart disease (CHD) risk. In practice, partially hydrogenated vegetable oils (PHVO) that contain both TFAs and other fatty acids are the unit of replacement and could be replaced with diverse alternative fats and oils. We performed quantitative estimates of CHD effects if a person's PHVO consumption were to be replaced with alternative fats and oils based on (1) randomized dietary trials and (2) prospective observational studies.

Subjects/methods: We performed meta-analyses of (1) the effects of TFAs on blood lipids and lipoproteins in controlled dietary trials and (2) associations of habitual TFA consumption with CHD outcomes in prospective cohort studies. On the basis of these results and corresponding findings for saturated fatty acids (SFA), cis-monounsaturated fatty acids (MUFA) and cis-polyunsaturated fatty acids (PUFA), we calculated the effects on CHD risk for replacing 7.5% of energy from three different PHVO formulations (containing 20, 35 or 45% TFAs) with butter, lard, palm or vegetable oils.

Results: In controlled trials, each 1% energy replacement of TFAs with SFAs, MUFAs or PUFAs, respectively, decreased the total cholesterol (TC)/high-density lipoprotein cholesterol (HDL-C) ratio by 0.31, 0.54 and 0.67; the apolipoprotein (Apo)-B/ApoAI ratio by 0.007, 0.010 and 0.011; and lipoprotein (Lp)(a) by 3.76, 1.39 and 1.11 mg/l (P<0.05 for each). We also included possible effects on C-reactive protein (CRP) of TFAs vs other fats from one trial. On the basis of these risk factor changes in controlled trials, CHD risk would be variably decreased by different fats and oils replacing 7.5% of energy from 20% TFA PHVO (CHD risk reduction: -2.7% (butter) to -9.9% (canola)); 35% TFA PHVO (-11.9% (butter) to -16.0% (canola)); or 45% TFA PHVO (-17.6% (butter) to -19.8% (canola)). In prospective cohort studies, each 2% energy replacement of TFAs with SFAs, MUFAs or PUFAs would lower CHD risk by 17% (95% confidence interval (CI)=7-25%), 21% (95% CI=12-30%) or 24% (95% CI=15-33%), respectively. On the basis of these associations in observational studies, CHD risk would be variably decreased by different fats and oils replacing 7.5% of energy from 20% TFA PHVO (CHD risk reduction: +0.5% (butter) to -21.8% (soybean)); 35% TFA PHVO (-14.4% (butter) to -33.4% (soybean)); or 45% TFA PHVO (-22.4% (butter) to -39.6% (soybean)). The demonstrated effects on TC/HDL-C, ApoB/ApoAI, Lp(a), and CRP in randomized feeding trials together accounted for approximately 65-80% and approximately 50% of the estimated risk reduction for replacing PHVO with animal fats and vegetable oils, respectively, that would be calculated from prospective cohort studies.

Conclusions: Effects on CHD risk of removing PHVO from a person's diet vary depending on the TFA content of the PHVO and the fatty acid composition of the replacement fat or oil, with direct implications for reformulation of individual food products. Accounting for the summed effects of TFAs on multiple CHD risk factors provides more accurate estimates of potential risk reduction than considering each risk factor in isolation, and approaches the estimated risk reduction derived from prospective cohort studies.

Similar Articles

Physiological basis of clinically used coronary hemodynamic indices

Author(s): Spaan JA, Piek JJ, Hoffman JI, Siebes M

Pressure-flow relations in coronary circulation

Author(s): Hoffman JI, Spaan JA

Pathophysiology of coronary artery disease

Author(s): Libby P, Theroux P

Multicentric inflammation in epicardial coronary arteries of patients dying of acute myocardial infarction

Author(s): Spagnoli LG, Bonanno E, Mauriello A, Palmieri G, Partenzi A, et al.

Chest pain relief by nitroglycerin does not predict active coronary artery disease

Author(s): Henrikson CA, Howell EE, Bush DE, Miles JS, Meininger GR, et al.

Exercise-induced ST depression in the diagnosis of coronary artery disease

Author(s): Gianrossi R, Detrano R, Mulvihill D, Lehmann K, Dubach P, et al.

Effect of myocardial ischemia on cardiac troponin I and T

Author(s): Carlson RJ, Navone A, McConnell JP, Burritt M, Castle MC, et al.

Prevalence and determinants of troponin T elevation in the general population

Author(s): Wallace TW, Abdullah SM, Drazner MH, Das SR, Khera A, et al.

Utility of myocardial perfusion imaging in patients with low-risk treadmill scores

Author(s): Poornima IG, Miller TD, Christian TF, Hodge DO, Bailey KR, et al.

Magnetic resonance spectroscopy in myocardial disease

Author(s): Hudsmith LE, Neubauer S

Accuracy of MSCT coronary angiography with 64-slice technology: first experience

Author(s): Leschka S, Alkadhi H, Plass A, Desbiolles L, Grünenfelder J, et al.

Characteristics of coronary plaques before angiographic progression determined by Multi-Slice CT

Author(s): Leber AW, von Ziegler F, Becker A, Becker CR, Reiser M, et al.

Influence of heart rate on the diagnostic accuracy of dual-source computed tomography coronary angiography

Author(s): Ropers U, Ropers D, Pflederer T, Anders K, Kuettner A, et al.

Radiation dose in computed tomography of the heart

Author(s): Morin RL, Gerber TC, McCollough CH

Radiation exposure during cardiac CT: effective doses at multi-detector row CT and electron-beam CT

Author(s): Hunold P, Vogt FM, Schmermund A, Debatin JF, Kerkhoff G, et al.

Prognostic value of dobutamine stress myocardial contrast perfusion echocardiography

Author(s): Tsutsui JM, Elhendy A, Anderson JR, Xie F, McGrain AC, et al.

N Engl J Med 331: 489-495

Author(s): Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, et al.

Major clinical events after coronary stenting

Author(s): Sutton JM, Ellis SG, Roubin GS, Pinkerton CA, King SB 3rd, et al.

Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease

Author(s): Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, et al.

Coronary revascularization in context

Author(s): Lange RA, Hillis LD

Coronary artery disease in Saudi Arabia

Author(s): Al-Nozha MM, Arafah MR, Al-Mazrou YY, Al-Maatouq MA, Khan NB, et al.

Diabetes mellitus in Saudi Arabia

Author(s): Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harthi SS, Arafah MR, et al.

Obesity in Saudi Arabia

Author(s): Al-Nozha MM, Al-Mazrou YY, Al-Maatouq MA, Arafah MR, Khalil MZ, et al.

Metabolic syndrome in Saudi Arabia

Author(s): Al-Nozha M, Al-Khadra A, Arafah MR, Al-Maatouq MA, Khalil MZ, et al.

Hypertension in Saudi Arabia

Author(s): Al-Nozha MM, Abdullah M, Arafah MR, Khalil MZ, Khan NB, et al.

Hyperlipidemia in Saudi Arabia

Author(s): Al-Nozha MM, Arafah MR, Al-Maatouq MA, Khalil MZ, Khan NB, et al.

Interaction between fatness and fitness on CVD risk factors in Asian youth

Author(s): Jekal Y, Kim ES, Im JA, Park JH, Lee MK, et al.

Body fatness and clustering of cardiovascular disease risk factors in Portuguese children and adolescents

Author(s): Ribeiro JC, Guerra S, Oliveira J, Andersen LB, Duarte JA, et al.

Changes in secondary prevention of coronary artery disease in the post-discharge period over the decade 1997-2007

Author(s): Pajak A, Jankowski P, Kawecka-Jaszcz K, Surowiec S, Wolfshaut R, et al.

Secondary prevention through cardiac rehabilitation: from knowledge to implementation

Author(s): Piepoli MF, Corrá U, Benzer W, Bjarnason-Wehrens B, Dendale P, et al.

Secondary prevention of coronary artery disease in hospital practice over the decade 1996-2006

Author(s): Jankowski P, Kawecka-Jaszcz K, Pajak A, Surowiec S, Wolfshaut R, et al.